Supplementary Figure 1. Effect of P2Et treatment on PD-L1 expression in cell lines. PD-L1 relative expression to GAPDH gene in B16-F10 (A) and 4T1 (B) cultured cells during 6, 12, 24 and 48 hours with one-half of the P2Et IC50 extract, cobaltous chloride (CoCl2) or ethanol (EtOH) analyzed by qRT-PCR and quantitated as a fold change against the control by using the 2\(^{-\Delta\DeltaCT}\) method. Geometric Mean Fluorescence Intensity (MFI) of surface (C and D) or intracellular (E and F) PD-L1 expression in B16-F10 (C and E) and 4T1 (D and F) cells. (G) PD-L1 relative expression to GAPDH gene in cells treated during 48 hours with one-half of the P2Et IC50 extract analyzed by qRT-PCR and quantitated as a fold change against the control (EtOH) by using the 2\(^{-\Delta\DeltaCT}\) method. (H) MFI of surface or intracellular PD-L1 expression represented as fold change against to the control (EtOH). In all cases data
are represented as the mean ± SEM. The $p$ values were calculated using a Mann-Whitney $U$ test or Kruskal-Wallis test with Dunn’s post-test. $^*p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$. 
Supplementary Figure 2. In vitro staining of surface PD-L1 after adding 10X more the therapeutic anti-PD-L1 antibody. Geometric Mean Fluorescence Intensity (MFI) of surface PD-L1 expression in B16-F10 (A) and 4T1 (B) cells at 1, 12, 24 or 48 hours after in vitro treatment with P2Et, therapeutic anti-PD-L1 or anti-PD-L1 + P2Et.
Supplementary Figure 3. Survival analysis in B16-F10 tumor-bearing mice treated with αPD-L1, P2Et, P2Et plus αPD-L1 or PBS as control.
Supplementary Figure 4. Effect of treatments in conventional dendritic cells and macrophages from tumor-draining lymph nodes. (A) Frequency of conventional DC and Geometric Mean Fluorescence Intensity (MFI) of PD-L1 expression in cDC from B16 tumor bearing-mice. (B) Frequency of macrophages and geometric MFI of PD-L1 expression in macrophages from B16 tumor bearing-mice (n=3). (C) Frequency of conventional DC and Geometric Mean Fluorescence Intensity (MFI) of PD-L1 expression in cDC from 4T1 tumor bearing-mice. (D) Frequency of macrophages and geometric MFI of PD-L1 expression in macrophages from 4T1 tumor bearing-mice (n=3). In all cases data are represented as the mean ± SEM.
Supplementary Figure 5. Effect of treatments in conventional dendritic cells, macrophages, MDSC and CD8⁺ T cells from spleen. Frequency of conventional DC (A), macrophages (B), MDSC (C), and CD8⁺ T cells (D) from B16 tumor bearing-mice (n=3) treated with PBS, P2Et, therapeutic anti-PD-L1 or anti-PD-L1 + P2Et. Frequency conventional DC (E), macrophages (F), MDSC (G), and CD8⁺ T cells (H) from 4T1 tumor bearing-mice (n=3) treated with PBS, P2Et, therapeutic anti-PD-L1 or anti-PD-L1 + P2Et. In all cases data are represented as the mean ± SEM.
Supplementary Figure 6. P2Et, αPD-L1 or P2Et plus αPD-L1 treatments modulates the immune response in breast 4T1 model. (A) Absolute numbers of CD45− and CD45+ cells per mg of tumor in mice treated with αPD-L1, P2Et, P2Et plus αPD-L1 or PBS (control). (B) Absolute numbers of CD4+ and CD8+ T cells per mg of tumor in each group of treated mice. (C) Frequency of activated CD44+ CD4+ and CD8+ T cells in tumor from each group of treated mice. (D) Number of MDSC-LC, M-MDSC and PMN-MDSC per mg of tumor from αPD-L1, P2Et, P2Et plus αPD-L1 or PBS treated mice. In all cases data are represented as the mean ± SEM. *p < 0.05, **p < 0.01.